CA
GILD icon

Continental Advisors’s Gilead Sciences GILD Stock Holding History

Continental Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$1.72M – 55
2022
Q4 		$1.72M Buy
+20,000
New +$1.58M 0.9% 38

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Continental Advisors's GILD Position: Q1 2026 in Review

Continental Advisors reduced its Gilead Sciences (GILD) stake by 14% in Q1 2026, selling an estimated $630K and leaving 28,367 shares worth $3.95M. The position accounts for 2.02% of the portfolio, ranked #18.

Continental Advisors first reported a position in GILD in Q3 2016 and has held it in 39 quarters since. The position peaked at $8.53M in Q2 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Continental Advisors held 28,367 shares of Gilead Sciences worth $3.95M as of Q1 2026.
  • Continental Advisors sold 4,500 Gilead Sciences shares in Q1 2026, an estimated $630K.
  • Gilead Sciences made up 2.02% of Continental Advisors's portfolio in Q1 2026, its #18 holding.
  • Continental Advisors first reported a position in Gilead Sciences in Q3 2016 and has held it in 39 quarters since.
  • Continental Advisors's Gilead Sciences position peaked at $8.53M in Q2 2021.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Continental Advisors's 13F filing for Q1 2026, filed 15 May 2026.